Alzheimer's disease vaccine - BELLUS Health

Drug Profile

Alzheimer's disease vaccine - BELLUS Health

Latest Information Update: 02 May 2008

Price : $50

At a glance

  • Originator Neurochem
  • Developer BELLUS Health; National Research Council Canada
  • Class Alzheimer vaccines; Antidementias; Neuroprotectants
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 02 May 2008 Discontinued - Preclinical for Alzheimer's disease in Canada (Parenteral)
  • 15 Apr 2008 Neurochem is now called BELLUS Health
  • 16 Feb 2007 Praecis Pharmaceuticals has been acquired by GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top